SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-029671
Filing Date
2024-03-12
Accepted
2024-03-12 08:30:09
Documents
13
Period of Report
2024-03-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atos-20240309.htm   iXBRL 8-K 44868
2 EX-99.1 atos-ex99_1.htm EX-99.1 16284
  Complete submission text file 0000950170-24-029671.txt   182633

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20240309.xsd EX-101.SCH 27477
14 EXTRACTED XBRL INSTANCE DOCUMENT atos-20240309_htm.xml XML 4494
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

IRS No.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 24740285
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)